UroGen Pharma (URGN) Accounts Payables (2016 - 2026)
UroGen Pharma's (URGN) quarterly Accounts Payables came in at $35.3 million in Q1 2026, up 16.57% YoY from $30.3 million in Q1 2025, and up 27.52% on a QoQ basis from $27.7 million in Q4 2025.
UroGen Pharma (URGN) Accounts Payables (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Accounts Payables data on file, last reported at $35.3 million in Q1 2026.
- Quarterly Accounts Payables rose 16.57% year-over-year to $35.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.3 million (up 16.57% YoY) and the FY2025 annual result came in at $27.7 million, up 1.04% from the prior year.
- Accounts Payables grew to $35.3 million in Q1 2026, from $27.7 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $35.3 million in Q1 2026 to a low of $8.6 million in Q2 2022.
- A 5-year average of $20.2 million and a median of $18.2 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables decreased 16.39% — and 2023, when it surged 89.7%.
- Tracing URGN's Accounts Payables over 5 years: stood at $12.4 million in 2022, then jumped by 33.55% to $16.5 million in 2023, then jumped by 65.87% to $27.4 million in 2024, then grew by 1.04% to $27.7 million in 2025, then increased by 27.52% to $35.3 million in 2026.
- The last three Accounts Payables figures came in at $35.3 million (Q1 2026), $27.7 million (Q4 2025), and $26.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 39.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.95 Mn |
| Mar 31, 2026 | 35.35 Mn |
| Dec 31, 2025 | 27.72 Mn |
| Sep 30, 2025 | 26.17 Mn |
| Jun 30, 2025 | 30.96 Mn |
| Mar 31, 2025 | 30.32 Mn |
| Dec 31, 2024 | 27.43 Mn |
| Sep 30, 2024 | 19.69 Mn |
| Jun 30, 2024 | 23.75 Mn |
| Mar 31, 2024 | 18.16 Mn |
| Dec 31, 2023 | 16.54 Mn |
| Sep 30, 2023 | 14.08 Mn |
| Jun 30, 2023 | 16.40 Mn |
| Mar 31, 2023 | 17.13 Mn |
| Dec 31, 2022 | 12.38 Mn |
| Sep 30, 2022 | 9.36 Mn |
| Jun 30, 2022 | 8.65 Mn |
| Mar 31, 2022 | 9.94 Mn |
| Dec 31, 2021 | 12.10 Mn |
| Sep 30, 2021 | 11.06 Mn |